Peptide Products
You are here:  Products » Peptide Products » Catalog Peptides - Hot Products »  Enfuvirtide (T-20)   
 
A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  ALL  HotProducts  
Search by Catalog Number :(eg.RP01001)
Search by Name :(eg.Parathyroid Hormone (PTH))
Search by Sequence : (One letter code)
Search by Sequence : (Three letter code)

 
Enfuvirtide (T-20)

Cat. No. Size Price Figures
RP17307-1 mg
 		1 mg
$ 165.00
MSDS:  20080915212928  (PDF)

STRUCTURE:
Enfuvirtide structure
Zoom

References:
  • Mink M, Mosier SM et al. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol. Oct 2005;79(19):12447-54.
  • Menzo S, Castagna A et al. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother. Sep 2004;48(9):3253-9.
  • Duffalo ML, James CW. Enfuvirtide: a novel agent for the treatment of HIV-1 infection. Ann Pharmacother. Oct 2003;37(10):1448-56.
Full Name
Enfuvirtide (T-20)
Alias ENF
Sequence
(one-letter code)		 Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2
Sequence
(three-letter code)		Ac-{TYR}{THR}{SER}{LEU}{ILE}{HIS}{SER}{LEU}{ILE}{GLU}
{GLU}{SER}{GLN}{ASN}{GLN}{GLN}{GLU}{LYS}{ASN}{GLU}
{GLN}{GLU}{LEU}{LEU}{GLU}{LEU}{ASP}{LYS}{TRP}{ALA}
{SER}{LEU}{TRP}{ASN}{TRP}{PHE}-NH2
C-TerminalNH2
Description36 residue synthetic peptide that inhibits HIV-1 fusion with CD4 cells. N-terminal acetylated, C-terminal amide. Enfuvirtide is the first in this class to reach market approval. Fusion inhibitors block the last step in the three-step viral entry process consisting of attachment, co-receptor binding and fusion, thereby preventing viral capsid entry into the host cell. Enfuvirtide has a unique mechanism of action and high viral target specificity, and in clinical trials has been shown to exhibit both high efficacy and low toxicity. Enfuvirtide is a peptide mimetic of an essential region within viral envelope glycoprotein gp41 that functions by blocking gp41 structural rearrangements at a transitional pre-fusion conformation.
FormulaC204H301N51O64
M.W.4491.88
Cas159519-65-0
Purity> 95%
StorageStore at -20°C. Keep tightly closed. Store in a cool dry place.
N-TerminalAc
* For Non-Clinical Research Use Only *


Our customer service is available 24 hours a day, Monday through Friday. You may contact us any time for assistance.